It is very uncertain whether naftopidil changes treatment withdrawals due to adverse events compared with eviprostat (phytotherapy) (very low certainty).
It is very uncertain whether postoperative MMC‐EMDA induction changes time to recurrence compared with postoperative BCG induction therapy (very low certainty).
The review found no eligible studies for this question.
Postoperative MMC‐EMDA with sequential BCG induction and maintenance may leads to lower time to recurrence compared with postoperative BCG induction and maintenance therapy (low certainty).
Postoperative MMC‐EMDA with sequential BCG induction and maintenance may leads to lower time to progression compared with postoperative BCG induction and maintenance therapy (low certainty).
It is very uncertain whether postoperative MMC‐EMDA with sequential BCG induction and maintenance changes serious adverse events compared with postoperative BCG induction and maintenance therapy (very low certainty).
Postoperative MMC‐EMDA with sequential BCG induction and maintenance may leads to lower disease‐specific survival compared with postoperative BCG induction and maintenance therapy (low certainty).
The review found no eligible studies for this question.
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with postoperative BCG induction therapy (very low certainty).
The review found no eligible studies for this question.
Postoperative MMC‐EMDA induction may leads to lower time to recurrence compared with MMC‐PD induction therapy (low certainty).
It is very uncertain whether postoperative MMC‐EMDA induction changes serious adverse events compared with MMC‐PD induction therapy (very low certainty).
Dose‐escalated RT showed no clear difference in time to death from prostate cancer compared with conventional dose RT (moderate certainty).
Dose‐escalated RT probably leads to higher severe RT toxicity (grade ≥ 3) compared with conventional dose RT (moderate certainty).